How to Reduce Impurity Risks in Biopharmaceuticals by Controlling Raw Material Quality

In the production of biopharmaceuticals such as monoclonal antibodies and recombinant proteins, the control of impurities is the core link determining drug safety and efficacy.

Three Hidden Dangers of Impurities Introduced by Raw Materials

1. Heavy Metal Ions: Trace amounts are necessary, but excess can cause oxidation and degradation of proteins.
2. Endotoxins and Pyrogens: Introduced from non-clean raw materials, they activate cell inflammatory responses.
3. Unknown Organic Impurities: Isomers or other organic impurities can produce toxic metabolites.

Strategies for Source Control

• Select Pharma-grade or Ultra-pure Raw Materials.
• Strict Lot-to-Lot Consistency.
• Use Microbe-Controlled Grade Products.